PATRICK J ZENNER
CIK 1139036 · Exec. Chairman & Interim CEO · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$13.87M
Companies
10
Total Filings
105
Lifetime Open-Market Net
-$2.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNAC | Director | 12,974 | $9.19 | $119.2K | $0 | 4 | 2026-01-06 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 55,248 | $0.88 | $48.7K | $0 | 8 | 2023-01-04 |
| WST | Director | 39,974 | $341.10 | $13.64M | -$2.16M | 33 | 2022-04-01 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | Director | — | — | — | $0 | 4 | 2012-01-09 |
| GERN | Director | 73,710 | $1.60 | $118.3K | $0 | 6 | 2010-05-21 |
| EXACT SCIENCES CORP (EXAS) Delisted | Exec. Chairman & Interim CEO | 124,994 | $104.91 | $13.11M | $0 | 5 | 2009-07-21 |
| CURAGEN CORP (CRGN) Delisted | Director | 10,000 | — | — | $27.5K | 5 | 2009-02-13 |
| SCIELE PHARMA, INC. (SCRX) Delisted | Director | 43,705 | — | — | $49.9K | 3 | 2008-04-28 |
| PRCS | Director | — | $29.14 | — | $0 | 1 | 2007-02-08 |
| DENDRITE INTERNATIONAL INC (DRTE) Delisted | Director | 19,000 | — | — | $0 | 1 | 2007-01-29 |
Recent Filings · Page 11 of 11
105 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-04-27 | SCIELE PHARMA, INC. (SCRX) Delisted | Grant (A) | +10,000 | $253.3K | EDGAR |
| 2007-03-12 | WST | Exer (M) | +2,750 | $31.9K | EDGAR |
| 2007-02-08 | PRCS | Disp (D) | — | $0 | EDGAR |
| 2007-01-29 | DENDRITE INTERNATIONAL INC (DRTE) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2007-01-05 | GERN | Grant (A) | +20,000 | $0 | EDGAR |
Showing 101–105 of 105
Prev
Page 11 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.